



Finding and Fueling Tomorrow's Advances in Precision Medicine

July 2024

A horizontal decorative bar composed of many small, vertical rectangular segments in various colors including blue, green, orange, and red.

This presentation is for information and discussion purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to purchase interests in any current or future investment vehicles managed by Nextech. This presentation is solely intended to provide high-level information about the relevant Nextech fund investment strategy, including limited information regarding investment activities which have or in the future could be undertaken pursuant to such strategy. If you are resident or established in a jurisdiction which (or acting on behalf of any person in respect of whom) receipt of such information would constitute fund marketing, then you should not review this presentation.

As of July 2, 2024. There can be no assurance that any Nextech fund or investment will be able to implement its investment strategy or achieve its investment objectives. Please see "Important Disclosures" on page 18. Past performance is not indicative of future results. There can be no assurance that historical trends will continue throughout the life of any fund, or that any investment made by Nextech will experience performance comparable to that associated with the portfolio companies referenced herein.

Nextech at a Glance





Zurich, Switzerland



Boston, MA, USA



San Francisco, CA, USA

‘One Nextech’



4

Active funds

USD 1.4b

Committed Capital

USD 552m

Distributed Capital

USD 398m

Dry Powder

Managed Assets



23

Private Companies

14

Public Companies

20

Board Seats

16

Fully Exited Companies

Portfolio Overview

About Nextech

Focus

We are a therapeutics specialist with **deep expertise in oncology** and disease adjacencies.

Expertise

We possess domain expertise and **leverage our Science Partners** and network of Key Opinion Leaders⁽¹⁾.


Strategy

We **actively allocate across the financing spectrum** to capture opportunities in a cyclical biotech market.

Execution

Our presence and relationships in **key US and European hubs** allows us to invest where the opportunities are.

Active Across the Financing Spectrum



Nextech plans to construct a portfolio of 20+/- companies, with the intent to **concentrate on roughly a dozen high conviction companies.**

An Entrepreneurial Team That is Committed to its Mission

Partners



Thilo Schroeder PhD
Managing Partner
Zurich



Kanishka Pothula
Managing Partner
San Francisco



Rocco Sgobbo
Managing Partner
Zurich



Jakob Loven PhD
Managing Partner
Zurich



Melissa McCracken PhD
Partner
Boston

Investment Team



Niresh Berinpanathan MS
Associate
Zurich/SF



Anna Guinot PhD
Associate
Zurich



Stella Paffenholz, PhD
Associate
Boston



Joanna Triscott, PhD
Senior Analyst
Zurich

Finance / Operations Team



Marco Weibel
CFO, Chief Compliance Officer (Switzerland)
Zurich



Ralph Stähli MS
Senior Controller
Zurich



Megan Graziano MTS
VP Operations, Chief Compliance Officer (US)
Boston



Maddie Ruf
Executive Assistant
Boston



Meriel Peccolo
Analyst
Zurich



Livia Sgobbo
Executive Assistant
Zurich



Jules Ketterlin
Analyst
Zurich



Akasha Abraham
Executive Assistant
San Francisco

Science Partners



Karl-Heinz Altmann PhD
ETH Zurich



Ben Cravatt PhD
Scripps Research Institute



Keith Flaherty MD
MGH



Philip D. Greenberg MD
Fred Hutch, Parker Institute



Richard A. Heyman PhD
Independent Advisor



William G. Kaelin MD
Dana-Farber, Harvard, HHMI



Antoni Ribas MD PhD
UC Los Angeles



Charles L. Sawyers MD
MSKCC, HHMI



Brenda A. Schulman PhD
Max Planck Institute



Kevan M. Shokat PhD
UCSF, UC Berkeley, HHMI



Paul Workman PhD
Institute of Cancer Research

Independent Board Members



Alexis Boris
Co-Founder & Oper. Chairman of Curie.Bio



Reto Schwager MBA
Member Executive Board Patrimonium Asset Mgmt. Ltd



Robbie Huffines MBA
Former Global Chair., Investment Banking at J.P. Morgan



Alfred Scheidegger PhD
Founder, Non-Executive Board Member
Zurich

Nextech's Active Portfolio

37	Active portfolio companies	20	Current BOD seats	23	Private	14	Public
----	----------------------------	----	-------------------	----	---------	----	--------

Private				Public			
 B	 B	 B	 B		 A1		
 B	 B	 B	 B				
 B B	 B	 B	 B				 B
 B	 B	 B	 B		 B	 B	
 B	 A2 B	 B	 A3 B				
			 B				
 B B							
				Recent Exit B BOARD (Current) ¹ B BOARD OBSERVER (Current) ¹			

^{A1} On May 2, 2024, Novartis (NYSE:NVS) announced that it has entered into a definitive agreement to acquire Mariana Oncology, in an all-cash merger transaction for a total equity value of approximately USD 1.0 billion. Announcement available [here](#).

^{A2} On January 8, 2024, Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), in an all-cash merger transaction for a total equity value of approximately USD 2.0 billion. The transaction [closed](#) on March 7, 2024.

^{A3} On April 3, 2024, Genmab A/S (NASDAQ: GMAB) announced that it has entered into a definitive agreement to acquire ProfoundBio, in an all-cash merger transaction for a total equity value of approximately USD 1.8 billion. Announcement available [here](#).

¹ Silverback Therapeutics entered into a definitive agreement with ARS Pharmaceuticals under which ARS merged with Silverback in an all-stock transaction. The combined company focuses on the potential regulatory approval and commercialization of ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis, operates under the name ARS Pharmaceuticals and trades on the Nasdaq Capital Market under the ticker symbol "SPRY." The merger [closed](#) on November 8, 2022.

As of July 2, 2024, There can be no assurance that any Nextech fund or investment will be able to implement its investment strategy or achieve its investment objectives. Please see "Important Disclosures" on page 18. Past performance is not indicative of future results. There can be no assurance that historical trends will continue throughout the life of any fund, or that any investment made by Nextech will experience performance comparable to that associated with the portfolio companies of Nextech funds is available upon request.

Seeking Excellence in Executing Our Investment Strategy

Discovering Value

Across Stages and Modalities



Creating Opportunities

Create de novo structured financing opportunities in select publicly traded companies



Fueling Success

Closely track and deploy capital towards our emerging high conviction cases




Leveraging Footprint

Execute investments outside the US and/or oncology



Disciplined execution coupled with a unique network of Science Partners and Key Opinion Leaders⁽¹⁾ enable a consistent process to maximize potential outcomes

Discovering Value Across All Stages and Modalities



Creating Later Stage Opportunities: Structured PIPEs



Jacob Chacko, MD
CEO

“The extended cash runway positions us well, and we look forward to presenting initial clinical data from our three clinical programs over the coming quarters while continuing to advance our mission of overcoming resistance in cancer.”



Barbara Weber, MD
CEO

“We are proud to have Nextech as a new investor, and to receive additional support from an outstanding group of current investors to further our mission to develop novel precision oncology treatments.”



- Leverage deep relationship with management and BoD to create opportunity
- Interrogate confidential data; process exclusive to Nextech
- Talk to indication specific experts and approach originators from the developed molecules
- Engage with our Science Partners



Create unique opportunities by leveraging Nextech’s deep network

Fueling Success in Emerging High-Conviction Cases

We believe our portfolio companies have the potential to be:

First – In – Class



Pioneering development of
KRas inhibitor blockbuster
opportunities

Best – In – Class



Accelerating the next wave of
targeted therapies

Broad Approach



Exploiting opportunities
beyond oncology

Leveraging Footprint Across Sectors and Geographies

Company	Unique Approach	Lead Indications
 Munich (Planegg), Germany	Versatile and customizable antibody-drug conjugates (ADCs)	Cancer indications
 Munich (Garching), Germany	Radiomolecular precision therapeutics, isotope supply and diagnostics	Cancer indications
 R&D Hub Berlin, Germany HQ in London, UK & New Jersey, US	Harnessing the body's natural process of RNA interference	Cardiovascular disease and rare blood disorder

Seeking to position our Portfolio Companies for Long-Term Success



Revolution Medicines to acquire biopharmaceutical company EQRx

The transaction will be concluded in November 2023.

August 2, 2023

Acquisition leading to \$1.1bn in proceeds to Revolution Medicines



THE WALL STREET JOURNAL.

HEALTH | PHARMA

Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for \$2 Billion

Ambrx is currently developing candidates for treatments for multiple types of cancer

PE Hub
Europe

PE Deals

BlackRock and Nextech betting on radiopharma with ITM

ITM supplies Novartis with an agent for its Pluvicto radiopharmaceutical, which reached sales of \$211m in the first quarter.

Craig McGlashan - 3 July 2023

Equity investment round of €255 million led by Temasek with participation from BlackRock Alternatives, Qatar Investment Authority (QIA), Nextech, ATHOS and Carbyne.



THE WALL STREET JOURNAL.

TECHNOLOGY | BIOTECH

Genmab Strengthens Oncology Portfolio With \$1.8 Billion Acquisition of ProfoundBio

The acquisition will give Genmab worldwide rights to a portfolio of next-generation antibody-drug conjugates



Proven track record of building successful companies



Bloomberg

Bayer to Buy Vividion Therapeutics for Up to \$2 Billion

- U.S. biotech was planning IPO before reaching takeover deal
- Transaction includes \$500 million in milestone payments



THE WALL STREET JOURNAL

BUSINESS

Bristol-Myers to Buy Turning Point Therapeutics for \$4.1 Billion

Deal would build out Bristol's position in lung-cancer treatments



THE WALL STREET JOURNAL

BUSINESS

Peloton Therapeutics' \$2.2 billion deal with Merck took root with an idea for clinical trials



Bloomberg

Novartis to Buy Mariana Oncology, Paying \$1 Billion Upfront

- Radiopharma firms are sought after by large drugmakers
- Novartis may make up to \$750 million in milestone payments



Appendix

Important Notices & Disclosures

This presentation (the "Presentation") is being furnished on a confidential basis to authorized recipients. This Presentation includes confidential, proprietary and trade secret information. By accepting this Presentation, each recipient agrees that (i) no portion of this Presentation may be reproduced or distributed in any format without the prior express written consent of Nextech Invest AG (together with its advisory affiliates, the "Firm" or "Nextech"), (ii) it will not copy, reproduce or distribute this Presentation, in whole or in part, to any person or party and (iii) it will keep confidential all information contained herein that is not already public.

This Presentation is for information and discussion purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to purchase interests in any current or future investment vehicles managed by Nextech (each a "Fund" and collectively, the "Funds"). A private offering of interests in any Fund shall be made only pursuant to a respective Fund's private placement memorandum ("PPM"), limited partnership agreement (as supplemented or amended from time to time, the "Partnership Agreement") and subscription document (the "Subscription Document" and together with the PPM and the Partnership Agreement, the "Governing Documents"), which describe certain risks related to such an investment, as well as other important information.

The delivery of this information shall not, under any circumstances, create any implication that the information contained herein is correct in all respects, including as of any time subsequent to the date thereof, and Nextech does not undertake any obligation to update or otherwise revise such information at any time after such date to reflect information that subsequently becomes available or a change in circumstances. Opinions, estimates and information expressed herein as of the date of this Presentation (or as of such other date noted herein) are subject to change without notice. This Presentation does not constitute a comprehensive report on the status and prospects of any Fund and such information, including any summaries, set forth herein does not purport to be complete or to contain all of the information that may be material to a recipient's decision to purchase any interests in a Fund and is subject to change at any time. This Presentation is subject to and qualified in its entirety by (i) reference to each Fund's PPM and Subscription Agreement, which contain additional information about the terms and conditions of an investment in each respective Fund and also contains risk disclosures that are important to any investment decision regarding each Fund and (ii) the detailed provisions of a Fund's Partnership Agreement. Each recipient should perform its own independent investigation and analysis of Nextech and the Funds and should carefully review the Governing Documents before making any decision to purchase any interests a Fund. This Presentation does not constitute a part of the Governing Documents.

Statements contained in this Presentation are reasonably based on expectations, estimates, projections, opinions and beliefs of Nextech and/or its principals on the date hereof. Forward looking statements are subject to a number of risks and uncertainties, some of which are beyond the control of Nextech, including among other things, the risks listed in each respective Fund's PPM and Subscription Document. No representation or warranty is made with respect to the reasonableness of any estimates, forecasts, illustrations, prospects, or returns, which should be regarded as illustrative only, or that any profits will be realized. Certain information contained in this Presentation constitutes "forward-looking statements" that can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "target," "project," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereon or comparable terminology. Any forward-looking statements included herein are based on Nextech's current opinions, assumptions, expectations, beliefs, intentions, estimates or strategies regarding future events, are subject to risks and uncertainties, and are provided for informational purposes only. Actual and future results and trends could differ materially, positively or negatively, from those described or contemplated in such forward-looking statements. Moreover, actual events are difficult to project and often depend upon factors that are beyond the control of Nextech. Given these uncertainties, no reliance should be placed on such forward-looking statements. No forward-looking statements contained in this Presentation constitute a guarantee, promise, projection, forecast or prediction of, or representation as to, future events. Nextech neither (i) assumes responsibility for the accuracy or completeness of any forward-looking statements, nor (ii) undertakes any obligation to update or revise any forward-looking statements for any reason after the date of this Presentation. Neither the delivery of this Presentation at any time nor any sale of interests in a Fund shall under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein and the date of this Presentation.

Certain of the information contained herein, particularly in respect of market data, economic and other forecasts and performance data, is from third-party sources. While Nextech believes such sources to be reliable, neither the Funds nor Nextech nor any of their respective affiliates nor employees have updated any such information through the date hereof or undertaken any independent review of information provided by third parties. Nextech does not make any representation or warranty, express or implied, with respect to the fairness, correctness, accuracy, reasonableness or completeness of any of the information contained herein (including but not limited to economic, market or other information obtained from third parties), and it expressly disclaims any responsibility or liability therefor. Third-party logos included herein are provided for illustrative purposes only. Inclusion of such logos does not imply affiliation with or endorsement by such firms or businesses. There is no guarantee that Nextech will work with any of the firms or businesses whose logos are included herein in the future.

The investment summaries and case studies presented herein are for illustrative purposes only and have been presented in order to provide an illustration of the types of investments made or considered by Nextech. It should not be assumed that investments made in the future will be comparable in quality or performance to the investments described herein. The information presented in these investment summaries and case studies are based primarily on Nextech's internal projections and market research conducted leading up to the initial investment in the relevant transaction. Except where otherwise indicated, such information has not been updated subsequent to the making of such internal analysis, is not intended to provide an update of company performance, and at the time made was and remains today subject to a number of actual contingencies that generally are not discussed herein. A complete list of all investments made Nextech, including investment performance, is available upon request.

There can be no assurance that historical trends will continue during the life of the Funds or any other investment vehicle managed by Nextech. Further, there can be no assurance that any of the listed potential future investment opportunities will in fact be acquired or, if acquired, acquired on the terms stated herein, or that any plans described herein will be realized on the terms expressed herein or at all.

Nothing contained herein should be construed as tax, accounting or legal advice or an investment recommendation.

Important Information Regarding Performance and Performance Projections

Statements contained in this Presentation (including those relating to current and future market conditions and trends in respect thereof) that are not historical facts are based on current expectations, estimates, projections, opinions, and/or beliefs of Nextech. Past, projected or target performance is not necessarily indicative, or a guarantee, of future results, and there can be no assurance that the Funds or any investment will achieve comparable results to those presented herein, that any Fund will be able to implement its investment strategy or achieve its investment objectives or that the returns generated by any investment will equal or exceed any past or projected returns presented herein. Any projections, forecasts or other estimated future returns, including estimates of returns or performance, set forth herein (the "Projections") are hypothetical, have been prepared and are set out for illustrative and discussion purposes only, and do not constitute a forecast. The Projections should not be relied upon and do not represent, and are not necessarily indicative of, the results that may be achieved by any Fund or investment. Projected or targeted performance has many inherent limitations. As a sophisticated investor, you acknowledge that you understand and accept such inherent limitations and agree to use the Projections for discussion purposes only.

The Projections are based largely on historical information. Nextech has not independently verified the accuracy or completeness of the information nor have the simulated results been independently verified or audited. Should any of the information used in the simulation prove to be inaccurate, the simulated or hypothetical results themselves may be inaccurate. Furthermore, the Projections are based upon certain assumptions that may change. There are numerous factors related to the markets in general or the implementation of any specific investment program that cannot be fully accounted for in the preparation of projected or targeted performance results, all of which can adversely affect actual investment results. The Projections are therefore subject to a number of important risks, qualifications, limitations, and exceptions. The models, estimates and assumptions of which the Projections are based are believed to be reasonable under the circumstances, but actual realized returns on a Fund's investments will depend on, among other factors, the ability to consummate attractive investments and to obtain the leverage reasonably assumed to be achievable based on current proposals from prospective financiers, future operating results, the value of the assets and market conditions at the time of disposition, any related transaction costs and the timing and manner of sale, all of which may differ from the assumptions and circumstances on which Projections are based.

The Projections have been prepared based on Nextech's view at the time the Projections were prepared in relation to future events and various estimations and assumptions made by Nextech or the applicable investments, including Nextech's belief about what results may be achievable in light of Nextech's experience with similar transactions, and estimations and assumptions about events that have not yet occurred, any of which may prove to be incorrect. Such estimations and assumptions may require modification as additional information becomes available and as economic and market developments warrant. Any such modification could be either favorable or adverse. While the Projections are based on assumptions that Nextech believed to be reasonable under the circumstances in which the Projections were prepared, they are subject to uncertainties, changes (including changes in economic, operational, political, legal, tax and other circumstances) and other risks, including, but not limited to, broad trends in business and finance, tax and other legislation affecting Nextech, the Funds, its investors, investments, monetary and fiscal policies, interest rates, inflation, market conditions, the level and volatility of trading markets, the availability and cost of short-term or long-term funding and capital, all of which are beyond the control of Nextech and any of which may cause the relevant actual, financial and other results to be materially different from the results expressed or implied by the Projections. Industry experts may disagree with the estimations and assumptions used in preparing the Projections.

No assurance, representation or warranty is made by any person that any of the Projections will be achieved, and no investor should rely on the Projections. None of Nextech, the Funds, any of their affiliates or any of their respective directors, officers, employees, partners, shareholders, advisors or agents makes any assurance, representation or warranty as to the accuracy of any of the Projections, estimates and assumptions.

EACH RECIPIENT ACKNOWLEDGES AND AGREES THAT IT IS RECEIVING THIS INFORMATION ONLY FOR THE PURPOSES STATED ABOVE AND SUBJECT TO ALL APPLICABLE CONFIDENTIALITY OBLIGATIONS AS WELL AS THE UNITED STATES SECURITIES LAWS PROHIBITING ANY PERSON WHO HAS RECEIVED MATERIAL, NON-PUBLIC INFORMATION FROM PURCHASING OR SELLING SECURITIES OF THE APPLICABLE ISSUER OR FROM COMMUNICATING SUCH INFORMATION TO ANY OTHER PERSON UNDER CIRCUMSTANCES IN WHICH IT IS REASONABLY FORESEEABLE THAT SUCH PERSON IS LIKELY TO PURCHASE OR SELL SUCH SECURITIES.